Roivant Sciences shares are trading higher after the company reported results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101 in ulcerative colitis, demonstrating improved efficacy from the induction to chronic period.
Portfolio Pulse from Benzinga Newsdesk
Roivant Sciences reported improved efficacy results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101 in ulcerative colitis, leading to higher trading of its shares.
June 22, 2023 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roivant Sciences shares are trading higher after reporting positive results from the TUSCANY-2 Phase 2b study of RVT-3101 in ulcerative colitis.
The positive results from the TUSCANY-2 Phase 2b study of RVT-3101 in ulcerative colitis indicate that the drug has potential for further development and commercialization. This news is likely to boost investor confidence in Roivant Sciences, leading to an increase in its share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100